Micron Biomedical

What Micron Biomedical does

Micron Biomedical is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Atlanta, Georgia, that develops a proprietary dissolvable microarray technology (also called Micro Array Patch or MAP) for needle-free delivery of vaccines and therapeutics. The technology consists of a 'peel and stick' button-like patch with micro-needles that painlessly penetrate the upper layers of the skin and dissolve to release medication in seconds to minutes, without producing sharps waste. The platform is thermostable, eliminating or reducing cold-chain storage requirements, and is designed for self-administration or administration by non-clinical personnel. Micron is advancing multiple vaccine programs using this platform, including measles-rubella (Phase 2 in infants), CDC-developed rotavirus CC24 (Phase 1, first-ever CDC-sponsored patch vaccine trial), seasonal trivalent influenza, an mRNA-based broadly-protecting flu vaccine with Zipcode Bio, and a Disease X rapid-response platform with CastleVax. The company also targets consumer therapeutics such as obesity, diabetes, pain management, and women's health for direct-to-consumer mail delivery.

Micron's revenue model is currently grant-driven rather than product-driven, with cumulative non-dilutive funding of approximately $50 million from the Bill & Melinda Gates Foundation ($43M+ total), CEPI ($3.7M), and BARDA ($2M prize), supplemented by $33M+ in Series A equity financing led by J2 Ventures and GHIC. The go-to-market approach is hybrid B2B/B2G: partnering with governments, WHO/CDC/GAVI/UNICEF/PATH for global health vaccination programs in low- and middle-income countries, with future expansion into healthcare provider networks and direct-to-consumer channels for self-administered therapeutics. Distribution is planned through government procurement, healthcare systems, and mail-based delivery enabled by the technology's thermostable, lightweight form factor.

The company has been recognized as the second most innovative smaller company on Fast Company's 2026 World's Most Innovative Companies list, won the Boston Biotech Week Biotech Medical Innovation Award in 2024, and was a Prix Galien Start-Up Category finalist. A 26,000+ square foot commercial-scale manufacturing facility in Alpharetta, Georgia opened in May 2026, positioning the company for pivotal clinical trials and a potential commercial launch estimated for 2027. Lead investors and grant funders (Gates Foundation, GHIC, J2 Ventures, CEPI, BARDA) hold board representation, and the leadership team combines decades of experience across medical devices, pharmaceuticals, and global health.

Name

Micron Biomedical

Legal name

Micron Biomedical, Inc.

Website

https://micronbiomedical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Micron Biomedical is a clinical-stage biopharmaceutical company developing proprietary dissolvable microarray patch technology for needle-free, thermostable delivery of vaccines and therapeutics, targeting global health organizations, governments, and future consumer therapeutics markets with potential commercial launch in 2027.

Ownership category

akta.pro rank

Product category

Drug Delivery Technology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)

akta.pro secondary industries

Needle-Free Injection Systems (Jet Injectors/Microneedle Patches) (HLAHAIAD), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

Keywords

• Needle-free drug delivery
• Dissolvable microarray patches
• Vaccine delivery technology
• Microneedle patch technology
• Thermostable biopharmaceutical delivery

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Grant Funding: The company receives significant grant funding from public health organizations and foundations to support R&D, clinical trials, and manufacturing scale-up. Sources include Bill & Melinda Gates Foundation ($43M+ total), CEPI ($3.7M), and BARDA ($2M prize).
2. Series A Equity Financing: Venture capital financing through Series A rounds (total $33M+ raised) led by J2 Ventures and GHIC to fund commercialization and manufacturing expansion.
3. Product Sales (Future): Planned commercialization of needle-free vaccine and therapeutic products. Potential commercial launch estimated for 2027 according to CEO statements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Micron Biomedical develops a proprietary dissolvable microarray (Micro Array Patch / MAP) technology that delivers vaccines and therapeutics painlessly through the skin without needles. The peel-and-stick button-like device penetrates upper skin layers, dissolves to release active compounds within seconds to minutes, and is removed as non-sharps waste. The company is advancing multiple clinical-stage vaccine candidates on this platform, including measles-rubella, rotavirus (CC24), seasonal influenza, mRNA-based flu, and a Disease X pandemic preparedness platform.

Product overview

Micron Biomedical is a clinical-stage life science company developing a proprietary dissolvable microarray technology (Micro Array Patch / MAP) as a unified platform for needle-free drug and vaccine delivery. The core technology is a 'peel & stick' button-like device that painlessly delivers medications into the upper skin layers within seconds to minutes. The company is advancing multiple vaccine products including measles-rubella (MR) vaccine, rotavirus vaccine (CC24), seasonal influenza vaccine, and mRNA-based flu vaccines, all delivered via this same platform technology. The platform eliminates cold chain requirements, reduces medical waste, and enables self-administration or administration by non-clinical personnel.

Differentiator

Problem solved

Functional benefit

Products and services

• Dissolvable Microarray Technology (Micro Array Patch / MAP) Proprietary dissolvable microarray (Micro Array Patch / MAP) platform that delivers vaccines and therapeutics painlessly through the skin without needles. The peel-and-stick button-like device penetrates upper skin layers, dissolves to release medication within seconds to minutes, and is removed as non-sharps waste. Serves as the foundation for all of Micron's vaccine and therapeutic candidates.
• Rotavirus Vaccine (CC24) Novel inactivated rotavirus vaccine developed by the CDC, delivered via Micron's dissolvable microarray technology. Designed as an alternative to oral administration for children in low- and middle-income countries where oral vaccines are less effective. Currently in Phase I clinical trial.
• Measles-Rubella (MR) Vaccine Needle-free version of the measles-rubella vaccine delivered via Micron's microarray technology. Reduces cold chain requirements and can be administered by community health workers. Demonstrated safety and immunogenicity in Phase I/II trials published in The Lancet, with the world's first Phase 2 trial of needle-free drug and vaccine technology in infants underway.
• Disease X Vaccine Platform Rapid-response vaccine platform combining Micron's microarray technology with CastleVax's Newcastle disease virus (NDV) platform, which can be quickly adapted to protect against different pathogens in response to novel viral threats. Developed for pandemic preparedness.
• mRNA-Based Broadly-Protecting Influenza Vaccine mRNA-based broadly-protecting influenza vaccine developed in collaboration with Zipcode Bio, delivered without needles via Micron's microarray technology. Targeted at pandemic preparedness and seasonal flu protection.
• Seasonal Influenza Vaccine (Trivalent) Trivalent seasonal flu vaccine delivered via Micron's dissolvable microarray technology. Demonstrated seroprotection in clinical trials published in The Lancet, with successful self-administration studies supporting at-home and field use.

Quantifiable outcome

• First needle-free vaccine demonstrated safe and effective in children as young as 9 months old
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• Emory UniversitycoreStrategic or Co-development Partner · 16 June 2025Emory University and Micron launched first-in-human clinical trial of rotavirus vaccine CC24 delivered via dissolvable microarray technology. Dr. Christina Rostad serves as lead investigator. Trial is first-ever CDC-sponsored clinical trial of vaccine delivered via patch technology.
• U.S. Centers for Disease Control and Prevention (CDC)coreStrategic or Co-development Partner · 16 June 2025CDC developed novel rotavirus vaccine CC24 and is sponsoring the first-ever clinical trial of a vaccine delivered via patch technology. Dr. Demetre Daskalakis, Director of CDC's National Center for Immunization and Respiratory Diseases, recognizes the potential of this trial.
• Dr. Jayne Morgan (Board Advisor)majorOthers · 9 June 2025Cardiologist and nationally recognized voice in health equity and vaccine education appointed to Board of Advisors to support Micron's mission to transform global access to vaccines and therapeutics.
• Zipcode BiocoreStrategic or Co-development Partner · 14 January 2025Collaboration to co-develop needle-free versions of mRNA based broadly-protecting influenza vaccines. Zipcode Bio co-founded by Nobel laureate Dr. Drew Weissman and Dr. Jason Zhang.
• CastleVaxcoreStrategic or Co-development Partner · 8 January 2025Partnership to study Micron's microarray technology combined with CastleVax's rapid-response vaccine platform based on Newcastle disease virus. The platform can be quickly adapted to protect against different pathogens for pandemic preparedness.
• Dr. Sandeep Patel (Advisor)majorOthers · 5 September 2024Former BARDA DRIVe Director and co-founder of KidneyX. Appointed to Micron's Board of Advisors to advance commercialization of needle-free technology.
• Dr. Seth Berkley (Scientific Advisor)majorOthers · 5 September 2024Global health pioneer and former GAVI CEO serves as Scientific Advisor to Micron's CEO. Dr. Berkley is committed to breaking down barriers to global vaccine access.
• GAVI (the Vaccine Alliance)majorStrategic or Co-development PartnerGAVI featured Micron's microarray technology in an article highlighting the opportunity to transform immunization coverage globally. Micron's measles patch tops Gavi's priority list for vaccine delivery innovations.
• PATHmajorStrategic or Co-development PartnerMicron partners with PATH and receives funding from this international nonprofit organization focused on global health innovation.
• Georgia Research AllianceminorStrategic or Co-development PartnerMicron partners with and receives funding support from the Georgia Research Alliance for economic development and research collaboration.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Vaxxas: Vaxxas is a clinical-stage biotech developing high-density microarray patches (HD-MAP) for vaccine and therapeutic delivery. It is the closest direct competitor to Micron, pursuing the same dissolvable/coat-and-dissolve microneedle approach with overlapping vaccine targets including measles-rubella and influenza.
• PharmaJet: PharmaJet develops needle-free jet injector systems for vaccine and drug delivery, including WHO-prequalified Tropis for fractional IPV dosing. It is a direct competitor in the needle-free vaccine administration space and the most commercially advanced peer with regulatory approvals and revenue.

Emerging players

• Enable Injections: Enable Injections develops wearable, large-volume subcutaneous drug delivery devices (enFuse) for biologics and high-volume therapeutics. While focused on injectors rather than dissolvable patches, it competes for the same self-administration/drug-delivery opportunity and partners with similar pharmaceutical customers.
• Inovio Pharmaceuticals: Inovio develops DNA-based vaccines delivered via its CELLECTRA electroporation device. While using a different delivery mechanism, Inovio competes in the same novel vaccine delivery space and targets similar infectious disease indications, including those pursued through global health partnerships.
• Corium (now part of Lotte Biologics affiliate): Corium developed transdermal drug delivery systems including the Corplex platform and was a pioneer in microarray patch technology. It represents an emerging player in novel drug delivery with potential overlap in microneedle and patch-based delivery for therapeutics and vaccines.

Broad incumbents

• West Pharmaceutical Services: West Pharmaceutical Services is a global leader in injectable drug containment and delivery components, including elastomeric closures, prefilled syringe systems, and drug delivery platforms. It serves the same pharma customers seeking innovative delivery technologies and has the scale and manufacturing capability to enter the patch space.
• LTS Lohmann Therapie-Systeme: LTS Lohmann is a global leader in transdermal therapeutic systems (TTS) and oral thin-film drug delivery. It has invested in Micron as a board member and offers adjacent drug-delivery capabilities and commercial-scale manufacturing that could be expanded into microneedle patches.
• Becton, Dickinson and Company (BD): BD is one of the largest global medical technology companies, with a dominant position in prefilled syringes, injection devices, and vaccine delivery. It serves as a broad incumbent whose legacy needle/syringe business could be disrupted by Micron's technology and which has resources to compete via acquisition or internal development.
• Sanofi Pasteur: Sanofi Pasteur is one of the world's largest vaccine manufacturers, producing measles, influenza, and other vaccines that Micron's platform could deliver as needle-free alternatives. It is a likely strategic partner or competitor for next-generation vaccine delivery across Micron's target indications.
• CSL Seqirus: CSL Seqirus is a major influenza vaccine manufacturer that could leverage Micron's MAP for needle-free flu vaccine delivery. It represents both a potential partnership target and a broad incumbent serving the same vaccination programs globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/micron-biomedical-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micron Biomedical